Studies / Graft-versus-host disease
Stem cell exosomes for graft-versus-host disease that failed other treatment
Kordelas L et al., Leukemia, 2014
Improvement reported, no control group
Improvement reported, no control group: Patients improved, but without a comparison group there is no way to tell whether the treatment caused it.
Level 1 of 5: One patient or a handful, described without a comparison. It can raise an idea; it cannot show that a treatment works.
See the full key- Design
- Case report
- People
- 1 person
- Made from
- Stem cells, tissue not specified here
- How it was given
- Repeated doses
What they found
Gut, skin, and mouth symptoms improved within about two weeks, and the steroid dose could be cut from 125 mg to 30 mg a day. The patient stayed stable for several months and died of pneumonia 7 months later.
What limits it
A single patient. The authors disclosed a patent application on the use of stem cell exosomes for inflammatory conditions.